Guselkumab (Tremfya®) is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||12/12/2020|
|Rapid review completed||17/02/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that guselkumab not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.